		田 田	ESMO's categories		
	1 (low benefit) 2 (low benefit)		3 (low benefit)	4 (substantial improvement)	5 (substantial improvement)
$\mathbf{med}_C \leq 12$	HR <sup>-</sup> > 0.7 <u>OR</u> gain < 1.5	$\begin{bmatrix} HR^{-} \le 0.65 \ \underline{AND} \\ gain \in [1.5, 2) \\ \underline{OR} \\ HR^{-} \in (0.65, 0.7] \ \underline{AND} \\ gain \ge 1.5 \end{bmatrix}$	$HR^- \le 0.65  \underline{AND}$ gain $\in [2, 3)$	$\begin{bmatrix} HR^- \le 0.65 & \underline{AND} \\ gain \ge 3 & \\ \underline{OR} \\ Increase in 2 year \\ survival \ge 10\% \end{bmatrix}$	Only achievable
$\mathbf{med}_C \in (12,24]$	$\begin{array}{l} HR^- > 0.75 \\ \hline OR \\ gain < 1.5 \end{array}$	$\begin{bmatrix} HR^- \le 0.7 & \underline{AND} \\ gain \in [1.5, 3) \\ \underline{OR} \\ HR^- \in (0.7, 0.75] & \underline{AND} \\ gain \ge 1.5 \end{bmatrix}$	$HR^- \le 0.7  \underline{AND}$ gain $\in [3, 5)$	$\begin{bmatrix} HR^- \le 0.7 \ \underline{AND} \\ gain \ge 5 \\ \underline{OR} \\ \hline \begin{bmatrix} Increase in 3 year \\ survival \ge 10\% \end{bmatrix}$	with toxicity, QoL or other bonus point adjustments
$med_C > 24$	$\begin{array}{l} HR^- > 0.75 \\ \underline{OR} \\ \underline{gain} < 4 \end{array}$	$\begin{bmatrix} HR^- \le 0.7 \ \underline{AND} \\ gain \in [4,6) \\ \underline{OR} \\ HR^- \in (0.7,0.75] \ \underline{AND} \\ gain \ge 4 \end{bmatrix}$	$\mathbf{HR}^- \le 0.7  \underline{\mathbf{AND}}$ $\mathbf{gain} \in [6, 9)$	$\begin{bmatrix} HR^- \le 0.7 \ \underline{AND} \\ gain \ge 9 \\ \underline{OR} \\ Increase \ in \ 5 \ year \\ survival \ge 10\% \end{bmatrix}$	

	IQWiG's categories	
minor added benefit	considerable added benefit	major added benefit
$\mathrm{HR}^+ \in [0.95,1)_{\mathrm{RR}}$	$\mathbf{HR}^+ \in [0.85, 0.95)_{\mathbf{RR}}$	$\mathrm{HR}^+ < 0.85_{\mathrm{RR}}$
	17 CHANCE OF 1 CHANCE AT	
	Mod-19W1G S <sub>HR</sub> (modified 19W1G method)	id)
minor added benefit	considerable added benefit	major added benefit

 $\mathrm{HR}^+ < 0.79_{\mathrm{HR}}$ 

 $HR^+ \in [0.79, 0.93)_{HR}$ 

 $HR^+ \in [0.93,1)_{HR}$